CERo Therapeutics Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236
CERo Therapeutics is continuing IND-enabling activities in preparation for submission of Investigational New Drug Application to FDA
- Go to the previous page
- 1
- …
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- …
- 64
- Go to the next page